2024 Volume 38 Issue 1 Pages 70-75
Precision medicine in biliary tract cancer is advancing rapidly with recent advances incomprehensive genomic panel (CGP). In the severe prognosis of biliary tract cancer, precision medicine is an important therapeutic strategy in addition to conventional cytotoxic anticancer drugs and immune checkpoint inhibitors. In particular, the types and rates of cancer gene aberrations vary by subpopulation, such as intrahepatic cholangiocarcinoma and gallbladder cancer, and there are many target molecules such as FGFR2 fusion gene and HER2 gene amplification that can lead to treatment. It is important to link the CGP to precision medicine in biliary tract cancer, including what to use and when to perform the test.
